This week at @SITCancer 2022, Marengo is presenting preclinical data that characterizes the mechanism of action and confirms robust anti-tumor activity for its novel T cell-activating antibody STAR0602. Read more: marengotx.com/news-investors…

Marengo is excited to present our compelling preclinical data at @SITCancer 2022! Stop by and meet the team in-person today and tomorrow at the poster hall. See you there! #SITC22

Thanks to Dr. James Gulley (@Gulleyj1), Marengo's SAB Co-Chair, and his team at National Cancer Institute for collaborating with us on STAR0602, for which we're presenting key preclinical data this week at @SITCancer. We are excited for what the future holds as we prepare to enter the clinic!

Happening today! Marengo’s Chief Development Officer, Dr. Ke Liu, will be presenting Marengo’s STAR platform and participating in a global development panel at BioCentury & BayHelix’s East-West Summit. Register now: conferences.biocentury.com/china-healthca…

#ICYMI Marengo recently presented key preclinical data on STAR0602 at ENA and SITC 2022! Check out the News page on our website to read the releases: marengotx.com/news-investors…

Today is the #GreatAmericanSmokeout! Marengo is proud to support the American Cancer Society Society in empowering people to quit smoking and in their mission to free the world from cancer. Learn more about the event: cancer.org/healthy/stay-a…

Wishing you a happy #Thanksgiving and restful weekend from our team to yours!

This year’s theme for the United Nations’s International Day of People with Disability is “transformative solutions for inclusive development”. We recognize the role of #innovation and work every day to create life-changing therapies that are accessible for all. #IDPD2022

At Marengo, we envision a world where everyone’s immune system can defeat #cancer. Want to join us in fearlessly pursuing new frontiers? Check out our job openings: marengotx.com/join-us/ #careers #jobs #biotech #hiring

Learn how Marengo is leading the next wave of IO breakthrough in "Uncovering the Hidden Secrets of T Cell Biology to Empower the Immune System to Protect" linkedin.com/pulse/uncoveri…

#TeamMarengo is growing! Join us in extending a warm welcome to our newest employees. We’re grateful to continue expanding our team in pursuit of our collective goal to envision lifelong protection against cancer. Interested? We’re still #hiring: marengotx.com/join-us/

This month, we came together for our offsite retreat! We reflected on all we’ve accomplished this year, and looked ahead to even more progress on behalf of patients in 2023. Importantly, we enjoyed each other’s company in-person! Thankful for the time together & for all to come.

The Marengo team is wishing you a wonderful holiday season! We hope that you and your loved ones have a well-deserved break and enjoy time with friends and family. #HappyHolidays to all!

As the year winds down and we look back at 2022, we’re incredibly grateful for the milestones that #TeamMarengo has accomplished over the past year. We look forward to what’s to come in 2023 as we expand the horizons for cancer treatment!

Marengo’s CEO, Zhen Su, MD; MBA, will be moderating the discussion panel “From Data to Medicine” at the upcoming Longwood Healthcare Leaders Pre-JPM Webconference at 10:50 a.m. ET on Thursday, January 5th! Learn more about the event and register here: longwoodhealthcareleaders.com

Today we announced that the first patient has been dosed over the holidays in START-001, a Phase 1/2 clinical trial evaluating STAR0602 as monotherapy in biomarker-enriched cohorts of patients with PD-1 refractory advanced solid tumors. Read more: marengotx.com/wp-content/upl…

Welcome to Kevin Chin, our new CMO! His experience in T cell directed oncology clinical development will be essential as we continue to advance STAR0602 and capitalize on the breadth of development opportunities afforded by our STAR platform. Learn more: marengotx.com/news-investors…

Congratulations to our newest promotees! We’re grateful for the exceptional work and enthusiasm you bring to #TeamMarengo every day, and we’re excited to see you grow in your new roles as we strive together to make lifelong protection against cancer a reality.

Marengo is proud to be partaking at the AACR Foundation Annual Meeting 2023. Today our Chief Development Officer will be an FDA expert panelist in a major symposium session and tomorrow our scientists will present a late-breaking abstract.

Exciting news! Marengo & Ipsen expand partnership to advance precision T cell engagers for ‘cold’ tumors. Up to $1.2B in payments. #CancerResearch #Oncology #partnerships